Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding

Vor Bio is licensing global rights a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It’s a pivot for Vor, which last month ceased its cancer R&D and announced it would explore strategic alternatives. The post Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3…

Read More

So What’s the Deal with ICHRA?

The number of US employees offered ICHRAs continues to grow. Yet, headwinds – including competition, individual coverage market uncertainty, and complexity – may hamper the ICHRA opportunity.  The post So What’s the Deal with ICHRA? appeared first on MedCity News.

Read More

Q&A: What Does the Budget Bill Mean for Your Health? 

LISTEN: Congress is considering roughly $800 billion in Medicaid cuts. You could feel the effects even if you’re not on the government program for people with low incomes and disabilities. KFF Health News chief Washington correspondent Julie Rovner explained how on WAMU’s “Health Hub,” June 18.  Health programs including Medicaid, Affordable Care Act subsidies, and…

Read More

A Health Economist to lead the NIH

By SAURABH JHA Early on in the COVID-19 pandemic a seroprevalence study from Santa Clara indicated that the viral spread was far greater than was believed. The study suggested that the infection fatality rate (IFR) was much lower than the case fatality rate and perhaps even lower than the suspected IFR. The researchers estimated that…

Read More

High Labor Costs Continue to Plague Providers, Data Shows

High labor costs remain an ongoing problem threatening providers’ bottom lines, according to new data from Kaufman Hall. The research revealed that medical groups’ median investment in each employed physician has reached more than $300,000 for the first time. The post High Labor Costs Continue to Plague Providers, Data Shows appeared first on MedCity News.

Read More